Abstract
The emergence of direct-acting antivirals has drastically changed the landscape of chronic hepatitis C (CHC) treatment. Because almost all patients with CHC can achieve a sustained virological response (SVR), the remaining issue is to identify those who need regular follow-up, especially for hepatocellular carcinoma (HCC) surveillance.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
